Current INSTI vs protease inhibitor or NNRTI use is linked to an increased risk for diabetes, which is slightly attenuated when adjusted for changes in BMI.

Dolutegravir is an HIV integrase strand transfer inhibitor (INSTI) that does not require pharmacokinetic boosting, has a long half-life allowing for once-daily dosing in treatment-naive patients ...

Sep. 20, 2024 — Researchers have shown that they can generate a strong immune response against HIV with two doses of a vaccine given one week ... Targeted Immune Intervention and Stopping ART in ...

The HIV pandemic has brought this issue to the ... the cost of ART–particularly combinations of drugs that include protease inhibitors (highly-active anti-retroviral therapy; HAART)–is ...

The committee found that at the start of the trial the researchers had no specific evidence that would indicate that DMF was either a protease inhibitor or that it would inhibit HIV in a clinical ...

Researchers at multiple AViDD centers confirm that the NIH has offered a 1-year, no-cost extension, but it doesn’t come with ...

Activation of macrophage TLR4 by bacterial endotoxins is important for the progression of sepsis, but the underlying ...